STIMOLA CURIOSITA’, PASSIONE E CORAGGIO
Genomic, immune, and clinical characterization of estrogen receptor-positive, HER2-low breast cancer to improve treatment personalization in early breast cancer patients: a translational, multicenter trial
Abstract
Validated biomarkers are needed for personalized, cost-effective treatment for ER+/HER2- breast cancer (BC). About 47-65% of ER+/HER2- tumors express low HER2 levels. Genomic, immune, and clinical differences exist between ER+/HER2-low and HER2-0 tumors. We aim to characterize HER-low and HER2-0 ER+ BC using tumor samples from adjuvant phase III trials, validating HER2-low as a prognostic/predictive biomarker. >300 BC tumor samples from 3 GIM trials will undergo RNA extraction for gene expression analysis, immune microenvironment assessment, and proteomic analysis. Survival data will be updated to validate biomarker associations.
Partenariato
- Università degli Studi di Genova
- Università degli Studi di Udine
- Università degli Studi di Napoli
Importo del progetto
Importo totale del progetto Euro 63.315,00
Importo del progetto Uniud Euro 54.000,00
Finanziamento Uniud Euro 9.315,00
Durata
- Dal 18/10/2023
- Al 17/10/2025
Link